Your activity: 20 p.v.
your limit has been reached. plz Donate us to allow your ip full access, Email: sshnevis@outlook.com

Management of lung irAEs in patients treated with immune checkpoint inhibitors*

Management of lung irAEs in patients treated with immune checkpoint inhibitors*
3.1. Pneumonitis
Work-up and evaluation:
  • Should include the following: Pulse oximetry and CT chest preferably with contrast if concerned for other etiologies such as pulmonary embolus.
  • For G2 or higher, may include the following infectious work-up: nasal swab, sputum culture, and sensitivity, blood culture and sensitivity, urine culture, and sensitivity.
  • COVID-19 evaluation – per institutional guidelines where relevant.
Grading Management
G1: Asymptomatic; confined to one lobe of the lung or <25% of lung parenchyma; clinical or diagnostic observations only.
  • Hold ICPi or proceed with close monitoring.
  • Monitor patients weekly with history and physical examination, pulse oximetry; may also offer chest imaging (CXR, CT) if uncertain diagnosis and/or to follow progress.
  • Repeat chest imaging in 3 to 4 weeks or sooner if patient becomes symptomatic.
  • In patients who have had baseline testing, may offer a repeat spirometry or DLCO in 3 to 4 weeks.
  • May resume ICPi with radiographic evidence of improvement or resolution if held. If no improvement, should treat as G2.
G2: Symptomatic; involves more than one lobe of the lung or 25 to 50% of lung parenchyma; medical intervention indicated; limiting instrumental ADL.
  • Hold ICPi until clinical improvement to ≤G1.
  • Prednisone 1 to 2 mg/kg/day and taper over 4 to 6 weeks.
  • Consider bronchoscopy with BAL ± transbronchial biopsy.
  • Consider empiric antibiotics if infection remains in the differential diagnosis after work-up.
  • Monitor at least once per week with history and physical examination, pulse oximetry, consider radiologic imaging; if no clinical improvement after 48 to 72 hours of prednisone, treat as grade 3.
  • Pulmonary and infectious disease consults if necessary.
G3: Severe symptoms; hospitalization required: involves all lung lobes or >50% of lung parenchyma; limiting self-care ADL; oxygen indicated.
G4: Life-threatening respiratory compromise; urgent intervention indicated (intubation).
  • Permanently discontinue ICPi.
  • Empiric antibiotics may be considered.
  • Methylprednisolone IV 1 to 2 mg/kg/day.
  • If no improvement after 48 hours, may add immunosuppressive agent. Options include infliximab or mycophenolate mofetil IV or IVIG or cyclophosphamide. Taper corticosteroids over 4 to 6 weeks.*
  • Pulmonary and infectious disease consults if necessary.
  • May consider bronchoscopy with BAL ± transbronchial biopsy if patient can tolerate.
ADL: activity of daily living; BAL: bronchoalveolar lavage; CT: computed tomography; CXR: chest x-ray; DLCO: diffusing capacity of lung for carbon monoxide; ICPi: immune checkpoint inhibitor; IV: intravenous; IVIG: intravenous immune globulin.
* Subset of patients may develop chronic pneumonitis and may require longer taper. Chronic pneumonitis is a described phenomenon where the incidence is not known, but <2%.
From: Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021; 39:4073. DOI: 10.1200/JCO.21.01440. Copyright © 2022 American Society of Clinical Oncology. Reproduced with permission from Wolters Kluwer Health. Unauthorized reproduction of this material is prohibited.
Graphic 116824 Version 5.0